Lentinan

	WikiDoc Resources for Lentinan
Articles
Most recent articles on Lentinan Most cited articles on Lentinan Review articles on Lentinan Articles on Lentinan in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lentinan Images of Lentinan Photos of Lentinan Podcasts & MP3s on Lentinan Videos on Lentinan
Evidence Based Medicine
Cochrane Collaboration on Lentinan Bandolier on Lentinan TRIP on Lentinan
Clinical Trials
Ongoing Trials on Lentinan at Clinical Trials.gov Trial results on Lentinan Clinical Trials on Lentinan at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lentinan NICE Guidance on Lentinan NHS PRODIGY Guidance FDA on Lentinan CDC on Lentinan
Books
Books on Lentinan
News
Lentinan in the news Be alerted to news on Lentinan News trends on Lentinan
Commentary
Blogs on Lentinan
Definitions
Definitions of Lentinan
Patient Resources / Community
Patient resources on Lentinan Discussion groups on Lentinan Patient Handouts on Lentinan Directions to Hospitals Treating Lentinan Risk calculators and risk factors for Lentinan
Healthcare Provider Resources
Symptoms of Lentinan Causes & Risk Factors for Lentinan Diagnostic studies for Lentinan Treatment of Lentinan
Continuing Medical Education (CME)
CME Programs on Lentinan
International
Lentinan en Espanol Lentinan en Francais
Business
Lentinan in the Marketplace Patents on Lentinan
Experimental / Informatics
List of terms related to Lentinan

Lentinan
Clinical data
Synonyms	(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
AHFS/Drugs.com	International Drug Names
ATC code	L03AX01 (WHO) ;
Identifiers
	IUPAC name β-D-glucopyranosyl-(1→6)-[β-D-glucopyranosyl-(1→3)-[β-D-glucopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)β-D-glucopyranosyl-(1→3)]-β-D-glucopyranose;
CAS Number	37339-90-5 ;
PubChem CID	37723;
ChemSpider	NA ;
KEGG	D01695 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C42H72O36
Molar mass	1152.99948 g/mol
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lentinan is an intravenous anti-tumor polysaccharide isolated from the fruit body of shiitake (Lentinula edodes). Lentinan has been approved as an adjuvant for stomach cancer in Japan since 1985.[2] Lentinan is one of the host-mediated anti-cancer drugs which has been shown to affect host defense immune systems.

Chemistry

Lentinan is a β-1,3 beta-glucan with β-1,6 branching. Molecular weight of lentinan is 500,000 Da. Specific rotation +14-22° (NaOH).

Research

An in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937.^[1] A pharmacological blend (MC-S) of lentinan, PSK, Ganoderma lucidum and Astragalus propinquus has also been shown to stimulate white blood cell production in vitro.^[2]

An in vivo experiment on mice, revealed lentinan is orally active (since clinical use of the drug is administered through an IV).^[3]

Limited clinical studies of cancer patients have associated lentinan with a higher survival rate, higher quality of life, and lower re-occurrence of cancer.^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]

Formulations containing Lentinan

Lentinex is a formulation featuring lentinan and is approved as a safe novel food in the EU.^[12]

References

↑ Sia GM, Candlish JK. (Mar 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytother Res. 13 (2): 133–7. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.
↑ Clark D, Adams M. (2007). "Using commercial nutraceutical mixes as immune stimulants: an in vitro proliferation study using Metabolic Cell-Support on non-stimulated human lymphocytes". Austr. J. Med. Herbal. 19: 108–111.
↑ Ng ML, Yap AT. (Oct 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". J Altern Complement Med. National University of Singapore. 8 (5): 581–9. doi:10.1089/107555302320825093. PMID 12470439.
↑ Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Adv Ther. 25 (8): 787–94. doi:10.1007/s12325-008-0079-x. PMID 18670743.
↑ Nimura H, Mitsumori N, Takahashi N, (Jun 2006). "[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]". Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983.
↑ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061.
↑ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer". Anticancer Res. 29 (7): 2739–45. PMID 19596954.
↑ Hazama S, Watanabe S, Ohashi M; et al. (July 2009). "Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer". Anticancer Res. 29 (7): 2611–7. PMID 19596936.
↑ Kataoka H, Shimura T, Mizoshita T; et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepatogastroenterology. 56 (90): 547–50. PMID 19579640.
↑ Isoda N, Eguchi Y, Nukaya H; et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepatogastroenterology. 56 (90): 437–41. PMID 19579616.
↑ Shimizu K, Watanabe S, Watanabe S; et al. (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepatogastroenterology. 56 (89): 240–4. PMID 19453066.
↑ EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). European Food Safety Authority (EFSA), Parma, Italy (2010), "Scientific Opinion on the safety of "Lentinus edodes extract" (Lentinex®) as a Novel Food ingredient" (PDF), EFSA Journal, 7 (8): 1685, doi:10.2903/j.efsa.2010.1685

Template:Carbohydrates

[pmid_=_10190187-1] Sia GM, Candlish JK. (Mar 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytother Res. 13 (2): 133–7. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.

[2] Clark D, Adams M. (2007). "Using commercial nutraceutical mixes as immune stimulants: an in vitro proliferation study using Metabolic Cell-Support on non-stimulated human lymphocytes". Austr. J. Med. Herbal. 19: 108–111.

[pmid_=_12470439-3] Ng ML, Yap AT. (Oct 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". J Altern Complement Med. National University of Singapore. 8 (5): 581–9. doi:10.1089/107555302320825093. PMID 12470439.

[pmid_=_18670743-4] Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Adv Ther. 25 (8): 787–94. doi:10.1007/s12325-008-0079-x. PMID 18670743.

[pmid_=_16897983-5] Nimura H, Mitsumori N, Takahashi N, (Jun 2006). "[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]". Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983.

[pmid_=_10522061-6] Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061.

[pmid19596954-7] Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer". Anticancer Res. 29 (7): 2739–45. PMID 19596954.

[pmid19596936-8] Hazama S, Watanabe S, Ohashi M; et al. (July 2009). "Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer". Anticancer Res. 29 (7): 2611–7. PMID 19596936.

[pmid19579640-9] Kataoka H, Shimura T, Mizoshita T; et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepatogastroenterology. 56 (90): 547–50. PMID 19579640.

[pmid19579616-10] Isoda N, Eguchi Y, Nukaya H; et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepatogastroenterology. 56 (90): 437–41. PMID 19579616.

[pmid19453066-11] Shimizu K, Watanabe S, Watanabe S; et al. (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepatogastroenterology. 56 (89): 240–4. PMID 19453066.

[12] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). European Food Safety Authority (EFSA), Parma, Italy (2010), "Scientific Opinion on the safety of "Lentinus edodes extract" (Lentinex®) as a Novel Food ingredient" (PDF), EFSA Journal, 7 (8): 1685, doi:10.2903/j.efsa.2010.1685

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]